When you purchase through links in our articles, we may earn a small commission. I asked AI to book dinner. ChatGPT, Claude, and Gemini may be aces at coding, but they're less than magical when it comes to booking a table for three. I can clearly see the day when we'll be able to summon ChatGPT, Claude, or Gemini on our phones, say something like "Hey ChatGPT, book a table for two at Outback Steakhouse tonight at 8," and ChatGPT will simply take care of it. All of the big AI providers are busy unveiling integrations for everyday services ranging from Spotify and DoorDash to AllTrails and the dinner reservation app Resy, with varying degrees of success.

OpenAI is racing to catch up to its greatest rival. OpenAI does not like to be left out. The week after Anthropic announced Claude Mythos Preview --an AI model that has put governments around the world on edge because of its potential ability to hack into banks, energy grids, and military systems--OpenAI shared a program that is uncannily similar. And just like Anthropic did with its model, OpenAI has, for cybersecurity purposes, restricted access to this new bot, called GPT-5.4-Cyber, to a small group of trusted users. This sequence has become something of a pattern: First Anthropic will make an announcement, and then OpenAI will follow suit.

In recent years, AI-assisted drug design methods have been proposed to generate molecules given the pockets' structures of target proteins. Most of them are atomlevel-based methods, which consider atoms as basic components and generate atom positions and types. In this way, however, it is hard to generate realistic fragments with complicated structures. To solve this, we propose D3FG, a functional-groupbased diffusion model for pocket-specific molecule generation and elaboration. D3FG decomposes molecules into two categories of components: functional groups defined as rigid bodies and linkers as mass points. And the two kinds of components can together form complicated fragments that enhance ligand-protein interactions. To be specific, in the diffusion process, D3FG diffuses the data distribution of the positions, orientations, and types of the components into a prior distribution; In the generative process, the noise is gradually removed from the three variables by denoisers parameterized with designed equivariant graph neural networks. In the experiments, our method can generate molecules with more realistic 3D structures, competitive affinities toward the protein targets, and better drug properties. Besides, D3FG as a solution to a new task of molecule elaboration, could generate molecules with high affinities based on existing ligands and the hotspots of target proteins.

Plus: OpenAI has ended its exclusive partnership with Microsoft. Elon Musk and Sam Altman are going to court over OpenAI's future Ahead of OpenAI's IPO, the court could rule on whether the company can exist as a for-profit enterprise. It could even oust its leadership. Musk, an OpenAI co-founder, claims he was deceived into bankrolling the firm under false pretenses. Find out how the trial could upend the global AI race . In a celebrated episode, a community of gnomes sneak out at night to steal underpants.

The bitter feud between Elon Musk and OpenAI boss Sam Altman has raged for years, but has mostly played out online in the form of accusations, counter-accusations and jibes. But starting on Tuesday, the beef between the two tech billionaires will shift to a much higher-profile forum: a federal courtroom in California, where their row will be the focus of a month-long trial. Being considered is Musk's claim that Altman - with whom he founded OpenAI - has swindled him out of millions of dollars and reneged on the ChatGPT-maker's original non-profit mission. Musk and Altman themselves will be among those to testify in a case in which the future of AI could be at stake. And while one will presumably emerge the winner, it's plausible that neither will emerge from the saga unscathed.